Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Regulus Therapeutics 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 USA

www.regulusrx.com P: 858-202-6300

Description:

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.

Key Statistics

Overview:

Market Capitalization, $K 145,332
Enterprise Value, $K 122,842
Shares Outstanding, K 65,465
Annual Sales, $ 0 K
Annual Net Income, $ -30,040 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -8,060 K
EBIT, $ -31,120 K
EBITDA, $ -31,050 K
60-Month Beta 1.57
% of Insider Shareholders 8.41%
% of Institutional Shareholders 92.38%
Float, K 59,959
% Float 91.59%
Short Volume Ratio 0.51

Growth:

1-Year Return 71.77%
3-Year Return -84.48%
5-Year Return -79.82%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 97.17%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.40 on 03/21/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm -1.59
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 06/29/22

RGLS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -109.21%
Return-on-Assets % -80.55%
Profit Margin % 0.00%
Debt/Equity 0.06
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.44
Book Value/Share 1.05
Interest Coverage -49.07
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar